The Medical Letter on Drugs and Therapeutics
Addendum: Brolucizumab (Beovu) for Age-Related Macular Degeneration
Download PDF:    US English
 Select a term to see related articles  Age-related macular degeneration   Beovu   brolucizumab   Drug Safety 

We reviewed brolucizumab (Beovu – Novartis) for treatment of neovascular (wet) age-related macular degeneration in our February 10 issue.1 On February 23, the American Society of Retina Specialists reported that 14 patients who received the drug have developed retinal vasculitis, a potentially vision-threatening complication.2

© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.